Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
Open Access
- 6 November 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3581
- https://doi.org/10.3390/jcm9113581
Abstract
Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disease, is characterized by telangiectases and arteriovenous malformations (AVMs). Untreated AVMs, especially in the lungs—pulmonary AVMs (PAVMs)—can result in morbidity with a decreased life expectancy. We have investigated whether HHT patients, systematically screened for HHT-related organ involvement and treated if needed, have a similar survival as persons without HHT. We included all individuals screened for HHT between 2004 and 2016 with a genetically or clinically confirmed diagnosis (HHT group) or excluded diagnosis (non-HHT control group). The social security number was used to confirm status as dead or alive in December 2019. We included 717 HHT patients and 471 controls. There was no difference in survival between the HHT and the non-HHT control group. The HHT group had a life expectancy of 75.9 years (95% confidence interval (CI) 73.3–78.6), comparable to the control group (79.3 years, 95% CI 74.8–84.0, Mantel–Cox test: p = 0.29). In conclusion, the life expectancy of HHT patients systematically screened for HHT-related organ involvement and treated if needed in an HHT center of excellence was similar compared to their controls, justifying systematic screening and treatment in HHT patients.This publication has 25 references indexed in Scilit:
- MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencingOrphanet Journal of Rare Diseases, 2013
- Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based studyAmerican Journal of Medical Genetics Part A, 2012
- International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasiaJournal of Medical Genetics, 2009
- Hereditary haemorrhagic telangiectasia: a clinical and scientific reviewEuropean Journal of Human Genetics, 2009
- Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective studyEuropean Respiratory Journal, 2009
- SMAD4 mutations found in unselected HHT patientsJournal of Medical Genetics, 2006
- Life expectancy in patients with hereditary haemorrhagic telangiectasiaQJM: An International Journal of Medicine, 2006
- Pulmonary arteriovenous malformationPostgraduate Medical Journal, 2002
- Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2Nature Genetics, 1996
- Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1Nature Genetics, 1994